The agreement includes an upfront payment of 62 million euros, with potential milestone payments reaching 664 million euros, alongside double-digit royalties on net sales. Bofanglutide, a long-acting GLP-1 receptor agonist, distinguishes itself from current market leaders through a bi-weekly dosing schedule, effectively halving the administration frequency required by competitors. Clinical trials in China and the United States have already confirmed the drug's efficacy in weight management and its safety profile.

For Menarini, the collaboration represents a strategic move to bolster its metabolic disease portfolio. For Gan & Lee, the deal serves as a gateway into highly regulated Western markets, marking a pivot from its traditional focus on insulin toward broader metabolic innovation. The companies are now preparing to initiate a global Phase 3 clinical program to meet regulatory requirements for commercial distribution, aiming to offer an alternative therapeutic option to millions of patients living with obesity or overweight.